Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$111.40 -1.0%	$109.58	$81.20 ▼ $131.49	$27.06B	1.23	665,335 shs	546,744 shs
NVAX Novavax	$9.52 -2.0%	$7.24	$5.01 ▼ $15.22	$1.58B	2.5	8.29 million shs	4.39 million shs
PFE Pfizer	$25.30 +0.9%	$24.64	$20.92 ▼ $30.43	$142.54B	0.52	45.10 million shs	29.13 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.85%	+3.01%	+2.30%	+10.65%	+32.12%
NVAX Novavax	+1.36%	+20.85%	+38.71%	+26.43%	-25.08%
PFE Pfizer	-0.36%	+1.87%	+2.49%	+6.64%	-11.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	1.6185 of 5 stars	3.4	2.0	0.0	0.0	1.9	0.8	0.0
NVAX Novavax	4.6245 of 5 stars	3.1	2.0	0.0	4.7	3.3	0.8	3.1
PFE Pfizer	4.9715 of 5 stars	3.2	3.0	4.2	4.5	3.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.76	Moderate Buy	$135.80	21.91% Upside
NVAX Novavax	2.25	Hold	$15.86	66.57% Upside
PFE Pfizer	2.39	Hold	$28.12	11.16% Upside

Current Analyst Ratings Breakdown

Latest BNTX, NVAX, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$138.00 ➝ $136.00
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$27.00 ➝ $28.00
8/5/2025	BNTX BioNTech	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$126.00 ➝ $134.00
8/5/2025	BNTX BioNTech	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$170.00 ➝ $150.00
7/22/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/16/2025	BNTX BioNTech	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $126.00
7/10/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$132.00 ➝ $133.00
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	9.00	N/A	N/A	$87.38 per share	1.27
NVAX Novavax	$682.16M	2.27	N/A	N/A	$0.23 per share	41.39
PFE Pfizer	$63.63B	2.26	$4.40 per share	5.75	$15.66 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$1.60	N/A	N/A	N/A	-12.20%	-1.84%	-1.59%	11/3/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.28	4.18	119.00	0.11	39.20%	-142.33%	28.65%	N/A
PFE Pfizer	$8.03B	$1.88	13.45	8.35	0.89	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest BNTX, NVAX, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	NVAX Novavax	-$0.07	$0.62	+$0.69	$0.62	$149.19 million	$239.24 million
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/4/2025	Q2 2025	BNTX BioNTech	-$1.41	-$1.60	-$0.19	-$1.82	$161.26 million	$306.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.80%	N/A	91.49%	16 Years

Latest BNTX, NVAX, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	8.61	8.48
NVAX Novavax	5.93	2.36	2.34
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
NVAX Novavax	53.04%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
NVAX Novavax	1.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.40 million	194.24 million	Optionable
NVAX Novavax	1,990	162.42 million	160.80 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

BNTX, NVAX, and PFE Headlines

Recent News About These Companies

Why Pfizer’s (PFE) Oncology Gamble is Finally Paying Off

1 hour ago | msn.com

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

August 19 at 10:10 AM | zacks.com

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Decreases Stock Holdings in Pfizer Inc. $PFE

August 19 at 9:12 AM | marketbeat.com

Wellington Management Group LLP Sells 36,497,190 Shares of Pfizer Inc. $PFE

August 19 at 8:10 AM | marketbeat.com

Edgar Lomax Co. VA Has $20.41 Million Stock Holdings in Pfizer Inc. $PFE

August 19 at 8:08 AM | marketbeat.com

Korea Investment CORP Sells 556,393 Shares of Pfizer Inc. $PFE

August 19 at 7:58 AM | marketbeat.com

Northern Trust Corp Grows Position in Pfizer Inc. $PFE

August 19 at 7:09 AM | marketbeat.com

Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?

August 19 at 5:50 AM | fool.com

Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?

August 19 at 4:50 AM | fool.com

American Century Companies Inc. Sells 122,607 Shares of Pfizer Inc. $PFE

August 19 at 4:26 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Receives $28.12 Average PT from Brokerages

August 19 at 2:07 AM | americanbankingnews.com

Health Canada Approves Pfizer's (PFE) Updated COVID-19 Vaccine for 2025-26

August 18 at 6:11 PM | gurufocus.com

Affinity Investment Advisors LLC Has $1.45 Million Holdings in Pfizer Inc. (NYSE:PFE)

August 18 at 7:23 AM | marketbeat.com

Pfizer sickle cell hopes dim as inclacumab fails in late-stage trial

August 18 at 7:13 AM | thepharmaletter.comT

Pfizer Inc. $PFE Holdings Boosted by Prospector Partners LLC

August 18 at 6:56 AM | marketbeat.com

Round Hill Asset Management Has $4.64 Million Stake in Pfizer Inc. (NYSE:PFE)

August 18 at 6:24 AM | marketbeat.com

Northwest & Ethical Investments L.P. Sells 55,619 Shares of Pfizer Inc. $PFE

August 18 at 6:19 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Acquired by Raymond James Financial Inc.

August 18 at 6:16 AM | marketbeat.com

Cresset Asset Management LLC Trims Stock Position in Pfizer Inc. (NYSE:PFE)

August 18 at 6:16 AM | marketbeat.com

These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year

August 18 at 5:23 AM | fool.com

Vestmark Advisory Solutions Inc. Invests $474,000 in Pfizer Inc. $PFE

August 18 at 5:10 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX, NVAX, and PFE Company Descriptions

BioNTech NASDAQ:BNTX

$111.40 -1.15 (-1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$112.76 +1.36 (+1.23%)

As of 07:13 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Novavax NASDAQ:NVAX

$9.52 -0.19 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$9.49 -0.03 (-0.26%)

As of 07:54 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$25.30 +0.23 (+0.90%)

Closing price 03:59 PM Eastern

Extended Trading

$25.26 -0.04 (-0.14%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time